



## Harnessing Cancer Vulnerability by Targeting the DNA Damage Response

Guest Editor:

**Dr. Angela Celetti**

Departement of Biomedical Science, Institute for Experimental Oncology and Endocrinology, National Research Council (CNR, ITALY), Via Pansini, 5, 80131, Naples, Italy

Deadline for manuscript submissions:

**closed (30 April 2022)**

### Message from the Guest Editor

Dear Colleagues,

In the precision medicine era, while agents that suppress oncogenic kinases have changed the standard of care for many cancers, no effective therapies are available for tumours, such as breast and ovarian cancer (OC), which are lacking in actionable driver cancer mutations. Luckily, the genome instability induced by the high frequency of DNA damage repair (DDR) defects has opened new avenues and treatment perspectives for such tumours.

My main interest in launching this Special Issue is to focus the discussion on innovative data in order to support clinical strategies for extending the advantages of PARP inhibitors beyond BRCA mutant cancers and towards a wider number of patients, through the use of novel biomarkers of homologous recombination repair deficiency as well as of predictive biomarkers of sensitivity. I would like to attract research and/or review articles to explore the potential application of PARP inhibitors in early treatment schemes, including neoadjuvant, adjuvant, and chemo/radio-prevention approaches.

Dr. Angela Celetti  
Guest Editor





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)